TOIPF yields 2.46% · JNJ yields 2.13%● Live data
📍 TOIPF pulled ahead of the other in Year 1
Combined, TOIPF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TOIPF + JNJ for your $10,000?
Thai Oil Public Company Limited, together with its subsidiaries, engages in the oil refining and distribution, petrochemicals, lube base oil, and other businesses in Thailand and internationally. It operates through Oil Refinery, Lube Base Oil Refinery, Petrochemical, Power Generation, Marine Transportation Services, Solvent, Ethanol, and Others segments. The company produces gasoline, diesel/gas oil, jet fuel, kerosene, fuel oil, and liquefied petroleum gas; and petrochemical products, such as paraxylene, benzene, toluene, and mixed xylenes. It also produces and distributes lube base oil, bitumen/asphalt, and other by-products, as well as special products, such as treated distillate aromatics extract and slack wax; and hydrocarbon and chemical solvents, and other chemicals. In addition, the company operates natural gas-fired combined-cycle co-generation power plants that generate and sell electricity, steam, and utilities to industrial users, as well as invests in other power generating companies and related business. Further, it is involved in the marine transportation of petroleum, petrochemical, and liquid chemical products; production of ethanol; provision of marine transportation services for crew and utilities; and biogas power generation and distribution. Additionally, the company provides human resource management services; and manufactures and sells linear alkyl benzene and related products. Thai Oil Public Company Limited was founded in 1961 and is headquartered in Bangkok, Thailand.
Full TOIPF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.